A detailed history of Voya Investment Management LLC transactions in Bicycle Therapeutics PLC stock. As of the latest transaction made, Voya Investment Management LLC holds 105,290 shares of BCYC stock, worth $1.55 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
105,290
Previous 124,620 15.51%
Holding current value
$1.55 Million
Previous $2.52 Million 5.35%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$19.58 - $27.24 $378,481 - $526,549
-19,330 Reduced 15.51%
105,290 $2.39 Million
Q2 2024

Dec 03, 2024

BUY
$20.02 - $24.69 $386,986 - $477,257
19,330 Added 18.36%
124,620 $2.52 Million
Q2 2024

Aug 14, 2024

SELL
$20.02 - $24.69 $243,343 - $300,106
-12,155 Reduced 8.89%
124,620 $2.52 Million
Q1 2024

Dec 06, 2024

BUY
$16.75 - $26.1 $527,373 - $821,758
31,485 Added 29.9%
136,775 $3.41 Million
Q1 2024

May 15, 2024

BUY
$16.75 - $26.1 $395,718 - $616,612
23,625 Added 20.88%
136,775 $3.41 Million
Q4 2023

Feb 14, 2024

SELL
$13.29 - $22.2 $2,724 - $4,551
-205 Reduced 0.18%
113,150 $2.05 Million
Q3 2023

Nov 14, 2023

BUY
$19.9 - $26.25 $497,201 - $655,856
24,985 Added 28.27%
113,355 $2.28 Million
Q2 2023

Aug 14, 2023

BUY
$18.95 - $28.67 $147,336 - $222,909
7,775 Added 9.65%
88,370 $2.26 Million
Q1 2023

May 15, 2023

BUY
$20.02 - $31.37 $291,391 - $456,590
14,555 Added 22.04%
80,595 $1.71 Million
Q4 2022

Feb 14, 2023

SELL
$20.37 - $32.9 $34,771 - $56,160
-1,707 Reduced 2.52%
66,040 $1.95 Million
Q3 2022

Mar 03, 2023

BUY
$17.49 - $28.44 $29,855 - $48,547
1,707 Added 2.58%
67,747 $1.58 Million
Q3 2022

Nov 14, 2022

BUY
$17.49 - $28.44 $1.18 Million - $1.93 Million
67,747 New
67,747 $1.58 Million

Others Institutions Holding BCYC

About BICYCLE THERAPEUTICS plc


  • Ticker BCYC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,676,100
  • Market Cap $436M
  • Description
  • Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...
More about BCYC
Track This Portfolio

Track Voya Investment Management LLC Portfolio

Follow Voya Investment Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Voya Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Voya Investment Management LLC with notifications on news.